Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib by Massimo Breccia

Get full text

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome by Massimo Breccia

Get full text

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached by Massimo Breccia

Get full text

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia by matteo molica, elisabetta abruzzese, massimo breccia

Get full text

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge by Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Massimo Breccia

Get full text

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios by Francesca Palandri, Massimo Breccia, Valerio De Stefano, Francesco Passamonti

Get full text

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia by Matteo Molica, Emilia Scalzulli, Gioia Colafigli, Robin Foà, Massimo Breccia

Get full text

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase by Fausto Castagnetti, Fausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia

Get full text

Editorial: Risk-stratification in myelodysplastic syndromes by Massimo Breccia, Francesca Vinchi, Francesca Vinchi, Massimiliano Bonifacio, Gianni Binotto, Gang Zheng

Get full text

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia by Massimo Breccia, Elisabetta Abruzzese, Mario Annunziata, Luigia Luciano, Simona Sica, Simona Sica

Get full text

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase by Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro, Jorge E. Cortes

Get full text

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients by Massimo Breccia, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, Fabio Efficace

Get full text

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia by Mario Annunziata, Massimiliano Bonifacio, Massimo Breccia, Fausto Castagnetti, Antonella Gozzini, Alessandra Iurlo, Patrizia Pregno, Fabio Stagno, Giorgina Specchia

Get full text

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination by Chiara Masucci, Mauro Passucci, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Alessandro Costa, Claudia Ielo, Maurizio Martelli, Massimo Breccia

Get full text

Case Report: Infectious prophylaxis in hematological malignancies by Mauro Passucci, Chiara Masucci, Francesca Paoletti, Claudia Ielo, Alessandro Costa, Ida Carmosino, Emilia Scalzulli, Maurizio Martelli, Giuseppe Gentile, Massimo Breccia

Get full text

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation by Maria Cristina Puzzolo, Massimo Breccia, Paola Mariglia, Gioia Colafigli, Sara Pepe, Emilia Scalzulli, Elena Mariggiò, Roberto Latagliata, Anna Guarini, Robin Foà

Get full text

Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report by Silvio Ligia, Emilia Scalzulli, Ida Carmosino, Giovanna Palumbo, Maria Chiara Molinari, Rebecca Poggiali, Alessandro Costa, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia

Get full text

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance by Massimo Breccia, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, Alessandra Iurlo

Get full text

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia by Alessandro Costa, Elisabetta Abruzzese, Roberto Latagliata, Olga Mulas, Ida Carmosino, Emilia Scalzulli, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Giovanni Caocci, Massimo Breccia

Get full text

Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy by Massimo Breccia, Francesca Chiodi, Aurelio Pio Nardozza, Diletta Valsecchi, Valentina Perrone, Diego Sangiorgi, Elisa Giacomini, Maria Chiara Rendace, Paola Coco, Eleonora Premoli, Luca Degli Esposti

Get full text